OpGen (OPGN) 10-Q 18 Jun 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	Jun. 10, 2015
Document and Entity Information
Entity Registrant Name	OPGEN INC
Entity Central Index Key	1293818
Document Type	10-Q
Document Period End Date	31-Mar-15
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Entity Current Reporting Status	No
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		10,718,347
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current assets
Cash and cash equivalents	$631,695	$749,517
Accounts receivable, net	91,984	503,983
Inventory, net	320,807	369,742
Prepaid expenses and other current assets	210,057	90,233
Total current assets	1,254,543	1,713,475
Property and equipment, net	568,602	587,956
Deferred IPO issuance costs	767,412	296,041
Other noncurrent assets	57,460	57,459
Total assets	2,648,017	2,654,931
Current liabilities
Accounts payable	1,059,253	1,160,081
Accrued compensation and benefits	430,972	423,099
Accrued liabilities	1,130,800	993,657
Deferred revenue	274,552	339,171
Derivative financial instruments	40,502
Short term notes payable	2,003,750	1,505,000
Current maturities of long-term capital lease obligation	122,027	100,499
Short-term convertible notes, net of discounts	1,500,006	1,500,000
Total current liabilities	6,561,862	6,021,507
Long-term capital lease obligation, less current maturities	163,726	134,149
Total liabilities	6,725,588	6,155,656
Commitments and contingencies (Note 10)
Redeemable convertible preferred stock
Total redeemable convertible preferred stock	4,736,640	4,564,899
Stockholders' deficit
Common stock, $.01 par value; 7,500,000 shares authorized; 493,483 and 493,178 shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively	4,936	4,932
Additional paid-in capital	90,548,318	88,701,737
Accumulated deficit	-99,367,465	-96,772,293
Total stockholders' deficit	-8,814,211	-8,065,624
Total liabilities, preferred stock and stockholders' deficit	2,648,017	2,654,931
Series A Convertible Redeemable Preferred Stock
Redeemable convertible preferred stock
Total redeemable convertible preferred stock	$4,736,640	$4,564,899

Condensed_Balance_Sheets_Paren

Condensed Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized	7,500,000	7,500,000
Common stock, shares issued	493,483	493,178
Common stock, shares outstanding	493,483	493,178
Series A Convertible Redeemable Preferred Stock
Preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, shares authorized	6,000,000	6,000,000
Preferred stock, shares issued	3,999,864	3,999,864
Preferred stock, shares outstanding	3,999,864	3,999,864
Preferred stock, liquidation preference	$7,999,728	$7,999,728

Condensed_Statements_of_Operat

Condensed Statements of Operations (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Revenue
Product sales	$184,179	$300,175
Laboratory services	35,241	169,250
Collaborations revenue	252,780	627,780
Total revenue	472,200	1,097,205
Operating expenses
Cost of products sold	115,389	136,107
Cost of services	95,430	97,918
Research and development	1,108,602	952,791
General and administrative	659,392	554,954
Sales and marketing	1,024,029	547,471
Total operating expenses	3,002,842	2,289,241
Operating loss	-2,530,642	-1,192,036
Other income (expense)
Interest income	35	37
Interest expense	-96,397	-8,202
Change in fair value of derivative financial instruments	31,831
Total other income (expense)	-64,531	-8,165
Net loss	-2,595,173	-1,200,201
Preferred stock dividends	-171,741	-110,815
Net loss available to common stockholders	($2,766,914)	($1,311,016)
Net loss per common share - basic and diluted	($5.61)	($3.62)
Weighted average shares outstanding - basic and diluted	493,463	362,537

Condensed_Statements_of_Cash_F

Condensed Statements of Cash Flows (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities
Net loss	($2,595,173)	($1,200,201)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	106,133	161,537
Noncash interest expense	17,123
Recovery of bad debt		-8,400
Share-based compensation expense	590,603	28,927
Inventory obsolescence expense	3,604	80,842
Change in fair value of derivative financial instruments	-31,831
Changes in operating assets and liabilities:
Accounts receivable	411,999	-617,535
Inventory	45,331	-155,759
All other assets	-25,854	69,092
Accounts payable	-319,483	69,811
Accrued compensation and other liabilities	145,016	-193,343
Deferred revenue	-64,619	451,372
Net cash used in operating activities	-1,717,151	-1,313,657
Cash flows from investing activities
Purchases of property and equipment	-10,034	-25,926
Net cash used in investing activities	-10,034	-25,926
Cash flows from financing activities
Proceeds from issuance of preferred stock, net of issuance costs		1,420,543
Proceeds from issuance of convertible notes and warrants, net of issuance costs	1,388,913
Proceeds from issuance of short term notes	500,000
Proceeds from exercise of stock options and warrants	55
Deferred IPO costs	-252,715
Payments on debt	-1,250	-1,250
Payments on capital lease obligations	-25,640	-27,443
Net cash provided by financing activities	1,609,363	1,391,850
Net (decrease) increase in cash and cash equivalents	-117,822	52,267
Cash and cash equivalents at beginning of period	749,517	1,400,345
Cash and cash equivalents at end of period	631,695	1,452,612
Supplemental disclosure of cash flow information
Cash paid during the period for interest	6,865	13,322
Supplemental disclosure of noncash investing and financing activities:
Acquisition of equipment purchased through capital leases	76,745
Exchange of demand note for convertible debt	300,000
IPO costs deferred and unpaid	$218,656

Organization

Organization	3 Months Ended
	Mar. 31, 2015
Organization
Organization	Note 1 - Organization
	OpGen, Inc., or the Company, was incorporated in Delaware in 2001. The Company’s headquarters and principal operations are in Gaithersburg, Maryland. The Company operates in one business segment.
	The Company is an early-stage company using rapid molecular testing and bioinformatics to assist healthcare providers to combat multi-drug resistant infections, or MDROs, as well as providing products and services for Whole Genome Mapping and analysis of microbial, plant, animal and human genomes for life sciences applications. The Company’s lead MDRO product is its Acuitas MDRO Gene Test, a CLIA lab-based test that provides a profile of MDRO resistant genes from patients screened for colonization or infection. In addition, the Company has more than ten years of experience mapping microbial and other genomes using its proprietary Whole Genome Mapping technology and providing related products and services to customers.
	The Company’s operations are subject to certain risks and uncertainties. The risks include rapid technology changes, the need to manage growth, the need to retain key personnel, the need to protect intellectual property and the need to raise additional capital financing on terms acceptable to the Company. The Company’s success depends, in part, on its ability to develop and commercialize its novel technology as well as raise additional capital.

Liquidity_and_Managements_Plan

Liquidity and Management's Plans	3 Months Ended
	Mar. 31, 2015
Liquidity and Management's Plans
Liquidity and Management's Plans	Note 2 - Liquidity and Management’s Plans
	The accompanying financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since inception, the Company has incurred, and continues to incur, significant losses from operations.
	The Company has funded its operations primarily through external investor financing arrangements.  The Company raised significant funds in 2013, 2014 and 2015, including:
		·	$4.0 million in two Series A Preferred Stock offerings during 2014 and 2013,
		·	$1.5 million through the issuance of convertible notes in 2014,
		·	$2.3 million in short-term demand notes in 2015 and 2014 (in the first quarter of 2015, $0.3 million of demand notes, held by an entity controlled by our chief executive officer, were settled as partial payment for a 2015 convertible note), and
		·	$1.5 million through the issuance of convertible notes in 2015.
	Subsequent to the first quarter, in April 2015, the Company raised $0.1 million through the issuance of additional demand notes with terms similar to the 2014 demand notes (Note 6) and $0.2 million through the issuance of an unsecured promissory note.  In May 2015, the Company completed its initial public offering, or IPO, pursuant to which the Company offered and sold 2,850,000 units, each consisting of one share of common stock and a detachable stock purchase warrant to purchase an additional share of common stock, at an initial offering price of $6.00 per unit (Note 11).  Of the total gross proceeds of $17.1 million, approximately $2.1 million was satisfied by exchanging outstanding demand notes.  After considering the demand notes, underwriting discounts and commissions and offering expenses, the total net cash proceeds to the Company was $12.8 million.  In connection with the IPO, all of the Company’s outstanding Series A Preferred Stock, 2014 convertible notes and 2015 convertible notes were converted into 7,374,864 shares of common stock.
	The principal purposes of the IPO were to obtain additional capital to support operations, establish a public market for the Company’s common stock and to facilitate its future access to the public capital markets. The Company currently intends to use the net proceeds as follows:
		·	approximately $5.0 million for sales and marketing activities, including expansion of the Company’s sales force to support the ongoing commercialization of the Acuitas MDRO gene test products and, when development is completed, the Acuitas Lighthouse MDRO Management System, and for working capital and general and administrative purposes;
		·	approximately $4.0 million for research and development related to the continued support of the completion of the development of the Acuitas Lighthouse MDRO Management System and future products in its pipeline; and
		·	the remainder for general and administrative expenses and for working capital and other general corporate purposes.
	The Company’s current operating assumptions (following the IPO), which include management’s best estimate of future revenue and operating expenses, indicate that current cash on hand will be sufficient to fund operations through at least the end of 2015.  In the event the Company is unable to successfully raise additional capital in 2016, the Company will not have sufficient cash flows and liquidity to finance its business operations as currently contemplated. Accordingly, in such circumstances the Company would be compelled to reduce general and administrative expenses and delay research and development projects, including the purchase of scientific equipment and supplies, until it is able to obtain sufficient financing.  The financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

Summary_of_significant_account

Summary of significant accounting policies	3 Months Ended
	Mar. 31, 2015
Summary of significant accounting policies
Summary of significant accounting policies	Note 3 - Summary of significant accounting policies
	Basis of presentation
	The accompanying interim condensed financial statements are unaudited.  These unaudited condensed financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission, or SEC, for interim financial information.  Accordingly, they do not include all the information and footnotes required by Generally Accepted Accounting Principles, or GAAP, for complete financial statements.  These unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December 31, 2014.  The unaudited interim condensed financial statements have been prepared on the same basis as the annual financial statements included in the Company’s registration statement on Form S-1 and, in the opinion of management, reflect all the adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of March 31, 2015 and the results of operations and cash flows for the three months ended March 31, 2015 and 2014.  The interim condensed results of operations are not necessarily indicative of the results that may occur for the full fiscal year. The December 31, 2014 balance sheet included herein was derived from the audited financial statements, but may not include all disclosures including notes required by GAAP for complete financial statements.
	Use of estimates
	In preparing financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  In the accompanying financial statements, estimates are used for, but not limited to, share-based compensation, allowances for doubtful accounts and inventories, valuation of derivative financial instruments, beneficial conversion features of convertible debt, deferred tax assets and liabilities and related valuation allowance, and depreciation and amortization and estimated useful lives of long-lived assets. Actual results could differ from those estimates.
	Fair value of financial instruments
	All current assets and liabilities are carried at cost, which approximates fair value, because of the short-term maturities of those instruments. Debt and capital leases are reflective of fair value based on instruments with similar terms available to the Company.
	Cash and cash equivalents
	The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents.  The Company has cash and cash equivalents deposited in financial institutions in which the balances occasionally exceed the federal government agency (FDIC) insured limits of $250,000. The Company has not experienced any losses in such accounts and management believes it is not exposed to any significant credit risk.
	Accounts receivable
	The Company’s accounts receivable result from revenues earned but not collected from customers. Credit is extended based on an evaluation of a customer’s financial condition and, generally, collateral is not required. Accounts receivable are due within 30 to 45 days and are stated at amounts due from customers. The Company evaluates if an allowance is necessary by considering a number of factors, including the length of time accounts receivable are past due, the Company’s previous loss history and the customer’s current ability to pay its obligation. If amounts become uncollectible, they are charged to operations when that determination is made. The allowance for doubtful accounts was $79,697 as of March 31, 2015 and December 31, 2014.
	At March 31, 2015, the Company had accounts receivable from three customers which individually represent 43%, 14% and 13% of total accounts receivable.
	Inventories
	Inventories are valued using the first-in, first-out method and stated at the lower of cost or market and consist of the following:
		March 31,			December 31,
		2015			2014
	Raw materials and supplies	$	123,569		$	40,749
	Work-in process	113,540			135,625
	Finished goods	83,698			193,368
	Total	$	320,807		$	369,742
	Inventories include the Argus Whole Genome Mapping Systems, reagents and supplies used for Argus consumable kits, and cards used for the Argus Whole Genome Mapping System as well as in the sales of the Company’s laboratory services. Inventory reserve for obsolescence and expirations was $871,420 and $867,816 at March 31, 2015 and December 31, 2014, respectively.
	Software development costs
	The cost to produce software that is sold as a separate product is capitalized when the software reaches technical feasibility in the development process. Technical feasibility begins when the product design is completed, which is typically when the final product specifications are determined. Costs incurred prior to technical feasibility are expensed as incurred as research and development. Capitalized costs are included in other assets when deferred and are included in cost of product sales as the software is sold.  There are no capitalized software costs at March 31, 2015 and December 31, 2014.
	Product warranty
	A warranty reserve is established upon the sale of any product that is covered by warranty based on the estimated cost of replacement parts during the warranty period. Warranty periods are twelve months. The reserve is adjusted during the warranty period to reflect the remaining estimated costs under the warranty.  The following table presents the accrued warranty reserve, the warranty expense and cost of replacement parts:
		March 31,			December 31,
		2015			2014
	Balance at beginning of period and year	$	2,750		$	6,500
	Warranty expense	750			4,077
	Cost of replacement parts and related delivery	(1,500		)	(7,827		)
	Balance at end of period and year	$	2,000		$	2,750
	Impairment of long-lived assets
	The Company assesses the recoverability of its long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. An impairment loss would be measured as the amount by which the carrying value of the asset exceeds the estimated fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. During the three months ended March 31, 2015 and 2014, the Company determined that there were no impaired long-lived assets.
	Deferred IPO issuance costs
	As of March 31, 2015 and December 31, 2014, the Company had deferred approximately $767,412 and $296,041 of legal and accounting fees related to its anticipated IPO.  The IPO was completed in the second quarter of 2015 and, as such, deferred and other IPO costs will be offset against IPO proceeds upon the consummation of the IPO. See Note 11.
	Redeemable convertible preferred stock
	The carrying value of the Company’s redeemable convertible preferred stock is increased by the accretion of related discounts, issuance costs and accrued but unpaid dividends so that the carrying amount will equal the redemption amount at the dates the stock becomes redeemable. As of March 31, 2015 and December 31, 2014, the Company has 3,999,864 of Series A redeemable convertible preferred stock, or Series A Preferred Stock, outstanding.  The Series A Preferred Stock is redeemable at the option of the holders of 70% of the outstanding shares of preferred stock, subject to certain additional requirements.  The Company’s redeemable convertible preferred stock is classified as temporary equity due to redemptions provisions outside of the Company’s control.  The redeemable convertible preferred stock was converted into shares of common stock in connection with the Company’s IPO in the second quarter of 2015.  See Note 11.
	Revenue recognition
	The Company recognizes revenue primarily from sales of the Argus System, sales of extended warranty service contracts for the Argus System, and from “funded software development” arrangements with collaborative parties. Revenue is recognized when the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred; the selling price is fixed or determinable; and collectability is reasonably assured. At times, the Company sells products and services, or performs software development, under multiple-element arrangements with separate units of accounting; in these situations, total consideration is allocated to the identified units of accounting based on their relative selling prices and revenue is then recognized for each unit based on its specific characteristics.
	Amounts billed to customers for shipping and handling are included in revenue when the related product or service revenue is recognized. Shipping and handling costs are included in cost of sales; the Company recognized revenue of $4,048 and $7,094 in the quarters ended March 31, 2015 and 2014, respectively, for shipping and handling.
	Revenue from sales of the Argus System
	When the Argus System is sold without the Genome Builder software, total arrangement consideration is recognized as revenue when the system is delivered to the customer. Ancillary performance obligations, including installation, limited customer training and limited consumables, are considered inconsequential and are combined with the Argus System as one unit of accounting.
	When the Argus System is sold with the Genome Builder software in a multiple-element arrangement, total arrangement consideration is allocated to the Argus System and to the Genome Builder software based on their relative selling prices. Selling prices are determined based on sales of similar systems to similar customers and, where no sales have occurred, on management’s best estimate of the expected selling price relative to similar products. Revenue related to the Argus System is recognized when it is delivered to the customer; revenue for the Genome Builder software is recognized when it is delivered to the customer.
	Revenue from sales of Genome Builder Software and consumables (on a stand-alone basis)
	Revenue is recognized for Genome Builder Software and for consumables, when sold on a standalone basis, upon delivery to the customer.
	Revenue from extended warranty service contracts
	The Company recognizes revenue associated with extended warranty service contracts over the service period in proportion to the costs expected to be incurred over that same period.
	Revenue from funded software development arrangements
	The Company’s funded software development arrangements generally consist of multiple-elements. Total arrangement consideration is allocated to the identified units of accounting based on their relative selling prices and revenue is then recognized for each unit based on its specific characteristics. When funded software development arrangements include substantive research and development milestones, revenue is recognized for each such milestone when the milestone is achieved and is due and collectible. Milestones are considered substantive if all of the following conditions are met: (1) the milestone is nonrefundable; (2) achievement of the milestone was not reasonably assured at the inception of the arrangement; (3) substantive effort is involved to achieve the milestone; and (4) the amount of the milestone appears reasonable in relation to the effort expended, the other milestones in the arrangement and the related risk associated with achievement of the milestone.
	Share-based compensation
	Share-based payments are recognized at fair value. The fair value of share-based payments to employees and directors is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option.  For all time-vesting awards granted, expense is amortized using the straight-line attribution method. For awards that contain a performance condition, expense is amortized using the accelerated attribution method. Share-based compensation expense recognized is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period.
	Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.
	Income taxes
	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to temporary differences between financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred income tax assets to the amount expected to be realized.
	Tax benefits are initially recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially, and subsequently, measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax authority, assuming full knowledge of the position and all relevant facts.
	The Company has federal net operating loss, or NOL, carryforwards of $76,267,809 at December 31, 2014. Despite the NOL carryforwards, which begin to expire in 2022, the Company may have future tax liability due to alternative minimum tax or state tax requirements. Also, use of the NOL carryforwards may be subject to an annual limitation as provided by Section 382 of the Internal Revenue Code of 1986, as amended, or the Code. There can be no assurance that the NOL carryforwards will ever be fully utilized.
	Loss per share
	Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of shares of common stock outstanding during the period.
	For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options and stock purchase warrants using the treasury stock method, and convertible preferred stock and convertible debt using the if-converted method.
	For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive. The number of anti-dilutive shares, consisting of common stock options, restricted stock units (in 2014), stock purchase warrants, convertible preferred stock and convertible debt (in 2015) exercisable or exchangeable into common stock which have been excluded from the computation of diluted loss per share, was 8.9 million and 3.6 million for the three months ended March 31, 2015 and 2014, respectively. The Company’s convertible preferred stock contains non-forfeitable rights to dividends, and therefore are considered to be participating securities; the calculation of basic and diluted income (loss) per share excludes net income (but not net loss) attributable to the convertible preferred stock from the numerator and excludes the impact of those shares from the denominator.
	Recent accounting pronouncements
	In May 2014, the Financial Accounting Standards Board, or FASB, issued guidance for revenue recognition for contracts, superseding the previous revenue recognition requirements, along with most existing industry-specific guidance. The guidance requires an entity to review contracts in five steps: 1) identify the contract, 2) identify performance obligations, 3) determine the transaction price, 4) allocate the transaction price, and 5) recognize revenue. The new standard will result in enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue arising from contracts with customers. The standard is effective for the Company’s reporting year beginning January 1, 2017 and early adoption is not permitted. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.
	In August 2014, the FASB issued guidance requiring management to evaluate on a regular basis whether any conditions or events have arisen that could raise substantial doubt about the entity’s ability to continue as a going concern. The guidance 1) provides a definition for the term ‘‘substantial doubt,’’ 2) requires an evaluation every reporting period, interim periods included, 3) provides principles for considering the mitigating effect of management’s plans to alleviate the substantial doubt, 4) requires certain disclosures if the substantial doubt is alleviated as a result of management’s plans, 5) requires an express statement, as well as other disclosures, if the substantial doubt is not alleviated, and 6) requires an assessment period of one year from the date the financial statements are issued. The standard is effective for the Company’s reporting year beginning January 1, 2017 and early adoption is permitted. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.
	In April 2015, the FASB issued accounting guidance requiring that debt issuance costs related to a recognized liability be presented on the balance sheet as a direct reduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected. The standard is effective for reporting periods beginning after December 15, 2015.  The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.
The Company has evaluated all other issued and unadopted Accounting Standards Updates and believes the adoption of these standards will not have a material impact on its results of operations, financial position, or cash flows.

Fair_value_measurements

Fair value measurements	3 Months Ended
	Mar. 31, 2015
Fair value measurements
Fair value measurements	Note 4 - Fair value measurements
	The Company classifies its financial instruments using a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:
		·		Level 1 - defined as observable inputs such as quoted prices in active markets;
		·		Level 2 - defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and
		·		Level 3 - defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions such as expected revenue growth and discount factors applied to cash flow projections.
	Financial assets and liabilities measured at fair value on a recurring basis
	The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the hierarchy.  The following tables present the fair value hierarchy for the Company’s financial assets and liabilities measured at fair value on a recurring basis at March 31, 2015 and December 31, 2014:
			Fair value at
			March 31,		Level 1		Level 2			Level 3
			2015
	Cash and cash equivalents		$	631,695	$	631,695	$	—		$	—
	Derivative warrant liability		$	40,502	$	—	$	—		$	40,502
			Fair value at
			December 31,		Level 1		Level 2			Level 3
			2014
	Cash and cash equivalents		$	749,517	$	748,048	$	1,469		$	—
	The Company’s Level 1 securities primarily consist of cash and cash equivalents, including money market funds and U.S Treasury Notes; the Company determines the estimated fair value for its Level 1 securities using quoted (unadjusted) prices for identical assets or liabilities in active markets.  The Company accounts for its derivative financial instruments, consisting solely of certain stock purchase warrants that contain non-standard anti-dilution provisions and/or cash settlement features, at fair value using level 3 inputs. We determine the fair value of these derivative liabilities using a hybrid valuation method that consists of a probability weighted expected return method that values the Company’s equity securities assuming various possible future economic outcomes while using an option pricing method (that treats all equity linked instruments as call options on the Company’s equity value with exercise prices based on the liquidation preference of the Series A Preferred Stock ) to estimate the allocation of value within one or more of the scenarios. Using this hybrid method, unobservable inputs included the Company’s equity value, the exercise price for each option value, expected timing of possible economic outcomes such as initial public offering, risk free interest rates and stock price volatility.  The following tables set forth a summary of changes in the fair value of Level 3 liabilities measured at fair value on a recurring basis for the quarter ended March 31, 2015:
	Description		Balance at		Established		Change in			Balance at
			December		in 2015		Fair Value			March 31,
			31, 2014							2015
	Derivative warrant liability		$	—	$	72,333	$	(31,831	)	$	40,502
	Financial assets and liabilities carried at fair value on a non-recurring basis
	The Company does not have any financial assets and liabilities measured at fair value on a non-recurring basis.
	Non-financial assets and liabilities carried at fair value on a recurring basis
	The Company does not have any non-financial assets and liabilities measured at fair value on a recurring basis.
	Non-financial assets and liabilities carried at fair value on a non-recurring basis
	The Company measures its long-lived assets, including property and equipment and intangible assets, at fair value on a non-recurring basis when they are deemed to be impaired. No such fair value impairment was recognized in the periods ended March 31, 2015 and 2014.

Series_A_redeemable_convertibl

Series A redeemable convertible preferred stock	3 Months Ended
	Mar. 31, 2015
Series A redeemable convertible preferred stock
Series A redeemable convertible preferred stock	Note 5 - Series A redeemable convertible preferred stock
	The Company’s Series A Preferred Stock is classified as temporary equity due to redemption provisions outside of the Company’s control.
	The Company issued 1,999,864 shares of Series A Preferred Stock in December 2013 at $1.00 per share in exchange for $1,999,864 in Convertible Promissory Notes.  In February 2014, the Company sold 1,405,096 shares of Series A Preferred Stock for gross proceeds of $1,405,096. In April 2014, the Company sold an additional 594,904 shares of Series A Preferred Stock for gross proceeds of $594,904.  As of March 31, 2015 and December 31, 2014, the Company had a total of 3,999,864 shares of Series A Preferred Stock outstanding, convertible into 3,999,864 shares of common stock.
	The Series A Preferred Stock has the right to receive non-cumulative dividends, at a rate of 8% per annum, when and if declared by the Board of Directors.  The Series A Preferred Stock has preference of payment over all other classes and series of capital stock of the Company with respect to dividends, payment on liquidation and payment on redemption. The liquidation and redemption preferences are at two times the Series A Preferred Stock purchase price. The Series A Preferred Stock holders are entitled to vote on all matters that come to stockholders on an as-converted basis with holders of the Common stock. In addition, the Series A Preferred Stock has broad based anti-dilution rights.
	The holders of Series A Preferred Stock have the right to convert such shares, at their option and at any time, into shares of common stock at the then-applicable conversion rate, as defined. The initial conversion rate is one common share for each preferred share, which may be adjusted for specified dilutive transactions.  Beginning in December 2020, the Company may be obligated to redeem shares of Series A Preferred Stock, if requested, by holders of at least 70% of the then-outstanding shares of preferred stock. The redemption, if requested, would take place in three equal annual installments. Series A redeemable convertible preferred stock would be redeemed at two times the original issue price per share plus all accrued and unpaid dividends. The redemptions are subject to certain equity adjustments for specified anti-dilution transactions, as defined.
	The Series A Preferred Stock was converted into shares of common stock in connection with the Company’s IPO in the second quarter of 2015.  See Note 11.

Debt

Debt	3 Months Ended
	Mar. 31, 2015
Debt
Debt	Note 6 - Debt
	Demand notes
	In the fourth quarter of 2014 and first quarter of 2015, the Company raised $2.3 million through the issuance of short-term demand notes.  In the first quarter of 2015, $0.3 million of demand notes, held by an entity controlled by our chief executive officer, were settled as partial payment for a 2015 convertible note.  The demand notes bear interest at 8% per annum, have a first priority security interest in the assets of the Company, and a term of approximately 4 months before the holder can demand payment.  The demand notes were tendered as payment for units in the Company’s IPO.  See Note 11.
	2014 convertible debt
	In July, August and September 2014, the Company raised $1.5 million through the issuance of convertible debt.  The debt is convertible, at the option of the holders or in certain cases at the Company’s option, into shares of Series A Preferred Stock or other potential equity securities.  The debt bears interest at 8% and is due in full on July 11, 2015.  The 2014 convertible debt was converted in connection with the Company’s IPO in the second quarter of 2015.  See Note 11.
	2015 convertible debt
	In February and March 2015, the Company raised $1.5 million in capital through the issuance of 8% secured convertible notes with detachable stock purchase warrants. The 2015 convertible notes were pre-payable by the Company without penalty at any time following the three month anniversary of the closing of an IPO; provided that before the six-month anniversary of the closing of an IPO, the 2015 convertible notes could only be prepaid out of newly issued capital subsequent to the IPO, and are puttable by the holder to the Company in the event of a defined default. The 2015 convertible notes are each convertible, at the election of the holder, into shares of Series A Preferred Stock, at a conversion rate of 1.25 shares of Preferred Stock for each $1.00 converted, if the conversion occurs prior to closing of an IPO, or into shares of common stock, at a conversion rate of one share of common stock for each $1.00 converted, if the conversion occurs after the closing of an IPO. The 2015 convertible note holders also received detachable stock purchase warrants exercisable for 225,011 shares of common stock at 110% of the IPO price and exercisable only if the IPO occurred, and then exercisable beginning on the six month anniversary of the closing of the IPO.
	As a result of net settlement features, the stock purchase warrants are considered derivative liabilities, were initially recorded at fair value (resulting in a debt discount) and are marked-to-market at each balance sheet date through earnings.  Additionally, the conversion option embedded in the convertible notes was determined to contain beneficial conversion features, resulting in the bifurcation of those features as an equity instrument (resulting in an additional debt discount).  After allocation of the gross proceeds to the detachable stock purchase warrants and beneficial conversion feature, the total debt discount recognized was equal to the face value of the 2015 convertible notes.  During the first quarter of 2015, the Company recognized a gain on the change in fair value of the derivative warrant liability of $31,831.
	The 2015 convertible debt was converted in connection with the Company’s IPO in the second quarter of 2015.  See Note 11.

Stockholders_equity_deficit

Stockholders' equity (deficit)	3 Months Ended
	Mar. 31, 2015
Stockholders' equity (deficit)
Stockholders' equity (deficit)	Note 7 - Stockholders’ equity (deficit)
	Stock options
	In 2002, the Company adopted the 2002 Stock Option and Restricted Stock Plan, or the 2002 plan, pursuant to which the Company’s Board of Directors could grant either incentive stock options or non-qualified stock options, shares of restricted stock, shares of unrestricted common stock, and other share-based awards to officers and employees. The 2002 plan authorized a pool of options to purchase a total of 3,036 shares of the Company’s common stock. The 2002 plan specified that, in a calendar year, the aggregate fair market value of incentive stock options, determined at the date of the grant, which became exercisable for the first time during any calendar year, could not exceed $100,000 for any participant. Stock options were granted at fair market value or at 110% of fair market value for those participants who were more than 10% stockholders. Generally, stock options have 10-year contractual terms, vest 25% per year and become fully exercisable after four years from the grant date.
	In 2008, the Company adopted the 2008 Stock Option and Restricted Stock Plan, or the 2008 plan, pursuant to which the Company’s Board of Directors may grant either incentive or non-qualified stock options or shares of restricted stock to directors, key employees, consultants and advisors. Upon adoption, the 2008 plan authorized grants of options to purchase a total of 7,570 shares of the Company’s common stock. The Company increased the number of shares of common stock available under the 2008 plan several times and as of March 31, 2015 there were 217,992 shares available for grant under the 2008 plan.  Only employees are eligible to have options granted as “incentive stock options.” Generally, stock options have 10-year contractual terms, vest 25% per year and become fully exercisable after four years from the grant date.
	For the three months ended March 31, 2015 and 2014, the Company recorded $590,603 and $28,927, respectively, of stock compensation expense.  The allocation of share-based compensation expense by operating expenses is as follows:
		Three months ended March 31,
		2015		2014
	Research and development	$	36,456	$	6,094
	General and administrative	83,299		22,060
	Sales and marketing	470,848		773
		$	590,603	$	28,927
	During the three months ended March 31, 2015, the Company granted stock options to acquire 826,500 shares of common stock at an exercise price of $0.61 per share.  The 2015 awards had a weighted average grant date fair value per share of $4.21.  The Company made no grants in the first quarter of 2014.  The Company has total stock options to acquire 1,229,494 shares of common stock outstanding at March 31, 2015.
	Restricted stock units
	In March 2014, the Company awarded restricted stock units to acquire 130,640 shares of common stock to its Chief Executive Officer. The restricted stock units were compensation for his service as Chief Executive Officer, or CEO, from October 2013 through June 2014 and were subject to forfeiture if he did not continue to perform management services through October 24, 2014. The restricted stock units vested on October 24, 2014 and 130,640 shares of common stock were issued to the CEO.
	Stock purchase warrants
	The Company has total stock purchase warrants to acquire 258,605 and 33,594 shares of common stock outstanding at March 31, 2015 and December 31, 2014, respectively.  In the second quarter of 2015 in connection with the Company’s IPO, the Company issued additional stock purchase warrants to investors and to its investment bankers.  See Note 11.

Commitments_and_contingencies

Commitments and contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and contingencies
Commitments and contingencies	Note 8 - Commitments and contingencies
	Operating leases
	During 2008, the Company relocated its headquarters to Gaithersburg, Maryland. The operating lease for that facility contained stated monthly rates with annual increases effective each anniversary date, and was scheduled to terminate in September 2012. In April 2011, this lease was modified and extended until September 2014; in March 2014, the Company extended the termination date to April 2015.  On March 20, 2015, the Company executed the Fifth Amendment to Lease Agreement, or the Fifth Amendment, with respect to the lease of its existing corporate facility. The Fifth Amendment, which includes an initial rent abatement period and subsequent annual rate increases, extends the term of the existing lease by 69 months effective May 1, 2015, with one additional five-year renewal at the Company’s election; the Company has the option to terminate the Fifth Amendment and extend the lease for up to one year.  The new extension contained similar terms and conditions, except that 50% of the monthly rental fee for October and November 2014 was abated. The Company is responsible for all utilities, repairs, insurance, and taxes under this operating lease. Rent expense under the Company’s operating leases for the three months ended March 31, 2015 and 2014 was $183,154 and $221,856, respectively.
	Capital leases
	The Company leases computer equipment, office furniture, and equipment under various capital leases. The leases expire at various dates through 2018. The leases require monthly principal and interest payments.

License_agreements_research_co

License agreements, research collaborations and development agreements	3 Months Ended
	Mar. 31, 2015
License agreements, research collaborations and development agreements
License agreements, research collaborations and development agreements
	Note 9 - License agreements, research collaborations and development agreements
	The Company is a party to two license agreements to acquire certain patent rights and technologies. Royalties are incurred upon the sale of a product or service which utilizes the licensed technology. Certain of the agreements require the Company to pay minimum royalties or license maintenance fees. The accompanying financial statements reflect $23,028 and $25,034 of total royalty expense for the three months ended March 31, 2015 and 2014, respectively.  In 2015, future minimum royalty fees are $20,000 under these agreements.
	In September 2013, the Company entered into a technology development agreement in which the Company would receive fixed milestone payments for meeting development milestones under the agreement. Since the milestones are substantive, the Company recognizes revenue in the periods in which the substantive milestones are achieved; the Company attained sixteen milestones during 2014. In addition, the Company received an upfront payment of $250,000, which is recognized on a straight-line basis over the term of the technology development agreement. The Company recognized total revenue of $252,780 and $627,780 during the three months ended March 31, 2015 and 2014, respectively, relating to this arrangement.

Related_person_transactions

Related person transactions	3 Months Ended
	Mar. 31, 2015
Related person transactions
Related person transactions	Note 10 - Related person transactions
	In December 2013, the Company purchased a BioMark HD DNA detection system and related instruments from Fluidigm Corporation, or Fluidigm, for a purchase price of $221,000. In March 2014, the Company entered into a supply agreement with Fluidigm under which Fluidigm supplies the Company with its microfluidic test platform for use in manufacturing the Acuitas MDRO Gene Test.  The Company’s Chief Executive Officer and Chair of the Board of the Company, is a director of Fluidigm.

Subsequent_events

Subsequent events	3 Months Ended
	Mar. 31, 2015
Subsequent events
Subsequent events	Note 11 - Subsequent events
	Equity plan
	The Company’s 2015 Equity Incentive Plan, or the 2015 Plan, was adopted by the Board of Directors and approved by stockholders in April 2015. The 2015 Plan became effective upon the execution and delivery of the underwriting agreement for the Company’s IPO. Following the effectiveness of the 2015 Plan, no further grants will be made under the 2008 Plan. The 2015 Plan provides for the granting of incentive stock options within the meaning of Section 422 of the Code to employees and the granting of non-qualified stock options to employees, non-employee directors and consultants. The 2015 Plan also provides for the grants of restricted stock, restricted stock units, stock appreciation rights, dividend equivalents and stock payments to employees, non-employee directors and consultants.
	Under the 2015 Plan, the aggregate number of shares of the common stock authorized for issuance may not exceed (1) 1,355,000 plus (2) the sum of the number of shares subject to outstanding awards under the 2008 Plan as of the 2015 Plan’s effective date that are subsequently forfeited or terminated for any reason before being exercised or settled, plus (3) the number of shares subject to vesting restrictions under the 2008 Plan on the 2015 Plan’s effective date that are subsequently forfeited. In addition, the number of shares that have been authorized for issuance under the 2015 Plan will be automatically increased on the first day of each fiscal year beginning on January 1, 2016 and ending on (and including) January 1, 2025, in an amount equal to the lesser of (1) 4% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (2) another lesser amount determined by the Board of Directors. Shares subject to awards granted under the 2015 Plan that are forfeited or terminated before being exercised or settled, or are not delivered to the participant because such award is settled in cash, will again become available for issuance under the 2015 Plan. However, shares that have actually been issued shall not again become available unless forfeited.
	Initial public offering
	On May 8, 2015, the Company completed its IPO pursuant to which the Company offered and sold 2,850,000 units, each consisting of one share of common stock and a detachable stock purchase warrant to purchase an additional share of common stock, at an initial offering price of $6.00 per unit.  Of the total gross proceeds of $17.1 million, approximately $2.1 million was satisfied by exchanging outstanding demand notes.  After considering the demand notes, underwriting discounts and commissions and offering expenses, the total net cash proceeds to the Company was $12.8 million.  On the IPO closing date, the underwriters exercised their over-allotment option to acquire an additional 422,500 stock purchase warrants.  In connection with the IPO, all of the Company’s outstanding Series A Preferred Stock, 2014 convertible notes and 2015 convertible notes were converted into 7,374,864 shares of common stock.
	The principal purposes of the IPO were to obtain additional capital to support the Company’s operations, establish a public market for its common stock and to facilitate its future access to the public capital markets. The Company currently intends to use the net proceeds from this offering as follows:
		·	approximately $5.0 million for sales and marketing activities, including expansion of the Company’s sales force to support the ongoing commercialization of the Acuitas MDRO gene test products and, when development is completed, the Acuitas Lighthouse MDRO Management System, and for working capital and general and administrative purposes;
		·	approximately $4.0 million for research and development related to the continued support of the Company’s completion of the development of the Acuitas Lighthouse MDRO Management System and future products in its pipeline; and
		·	the remainder for general and administrative expenses and for working capital and other general corporate purposes.

Summary_of_significant_account1

Summary of significant accounting policies (Policies)	3 Months Ended
	Mar. 31, 2015
Summary of significant accounting policies
Basis of presentation	Basis of presentation
	The accompanying interim condensed financial statements are unaudited.  These unaudited condensed financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission, or SEC, for interim financial information.  Accordingly, they do not include all the information and footnotes required by Generally Accepted Accounting Principles, or GAAP, for complete financial statements.  These unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December 31, 2014.  The unaudited interim condensed financial statements have been prepared on the same basis as the annual financial statements included in the Company’s registration statement on Form S-1 and, in the opinion of management, reflect all the adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of March 31, 2015 and the results of operations and cash flows for the three months ended March 31, 2015 and 2014.  The interim condensed results of operations are not necessarily indicative of the results that may occur for the full fiscal year. The December 31, 2014 balance sheet included herein was derived from the audited financial statements, but may not include all disclosures including notes required by GAAP for complete financial statements.
Use of estimates	Use of estimates
	In preparing financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  In the accompanying financial statements, estimates are used for, but not limited to, share-based compensation, allowances for doubtful accounts and inventories, valuation of derivative financial instruments, beneficial conversion features of convertible debt, deferred tax assets and liabilities and related valuation allowance, and depreciation and amortization and estimated useful lives of long-lived assets. Actual results could differ from those estimates.
Fair value of financial instruments	Fair value of financial instruments
	All current assets and liabilities are carried at cost, which approximates fair value, because of the short-term maturities of those instruments. Debt and capital leases are reflective of fair value based on instruments with similar terms available to the Company.
Cash and cash equivalents	Cash and cash equivalents
	The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents.  The Company has cash and cash equivalents deposited in financial institutions in which the balances occasionally exceed the federal government agency (FDIC) insured limits of $250,000. The Company has not experienced any losses in such accounts and management believes it is not exposed to any significant credit risk.
Accounts receivable	Accounts receivable
	The Company’s accounts receivable result from revenues earned but not collected from customers. Credit is extended based on an evaluation of a customer’s financial condition and, generally, collateral is not required. Accounts receivable are due within 30 to 45 days and are stated at amounts due from customers. The Company evaluates if an allowance is necessary by considering a number of factors, including the length of time accounts receivable are past due, the Company’s previous loss history and the customer’s current ability to pay its obligation. If amounts become uncollectible, they are charged to operations when that determination is made. The allowance for doubtful accounts was $79,697 as of March 31, 2015 and December 31, 2014.
	At March 31, 2015, the Company had accounts receivable from three customers which individually represent 43%, 14% and 13% of total accounts receivable.
Inventories	Inventories
	Inventories are valued using the first-in, first-out method and stated at the lower of cost or market and consist of the following:
		March 31,			December 31,
		2015			2014
	Raw materials and supplies	$	123,569		$	40,749
	Work-in process	113,540			135,625
	Finished goods	83,698			193,368
	Total	$	320,807		$	369,742
	Inventories include the Argus Whole Genome Mapping Systems, reagents and supplies used for Argus consumable kits, and cards used for the Argus Whole Genome Mapping System as well as in the sales of the Company’s laboratory services. Inventory reserve for obsolescence and expirations was $871,420 and $867,816 at March 31, 2015 and December 31, 2014, respectively.
Software development costs	Software development costs
	The cost to produce software that is sold as a separate product is capitalized when the software reaches technical feasibility in the development process. Technical feasibility begins when the product design is completed, which is typically when the final product specifications are determined. Costs incurred prior to technical feasibility are expensed as incurred as research and development. Capitalized costs are included in other assets when deferred and are included in cost of product sales as the software is sold.  There are no capitalized software costs at March 31, 2015 and December 31, 2014.
Product warranty	Product warranty
	A warranty reserve is established upon the sale of any product that is covered by warranty based on the estimated cost of replacement parts during the warranty period. Warranty periods are twelve months. The reserve is adjusted during the warranty period to reflect the remaining estimated costs under the warranty.  The following table presents the accrued warranty reserve, the warranty expense and cost of replacement parts:
		March 31,			December 31,
		2015			2014
	Balance at beginning of period and year	$	2,750		$	6,500
	Warranty expense	750			4,077
	Cost of replacement parts and related delivery	(1,500		)	(7,827		)
	Balance at end of period and year	$	2,000		$	2,750
Impairment of long-lived assets	Impairment of long-lived assets
	The Company assesses the recoverability of its long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. An impairment loss would be measured as the amount by which the carrying value of the asset exceeds the estimated fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. During the three months ended March 31, 2015 and 2014, the Company determined that there were no impaired long-lived assets.
Deferred IPO issuance costs	Deferred IPO issuance costs
	As of March 31, 2015 and December 31, 2014, the Company had deferred approximately $767,412 and $296,041 of legal and accounting fees related to its anticipated IPO.  The IPO was completed in the second quarter of 2015 and, as such, deferred and other IPO costs will be offset against IPO proceeds upon the consummation of the IPO. See Note 11.
Redeemable convertible preferred stock	Redeemable convertible preferred stock
	The carrying value of the Company’s redeemable convertible preferred stock is increased by the accretion of related discounts, issuance costs and accrued but unpaid dividends so that the carrying amount will equal the redemption amount at the dates the stock becomes redeemable. As of March 31, 2015 and December 31, 2014, the Company has 3,999,864 of Series A redeemable convertible preferred stock, or Series A Preferred Stock, outstanding.  The Series A Preferred Stock is redeemable at the option of the holders of 70% of the outstanding shares of preferred stock, subject to certain additional requirements.  The Company’s redeemable convertible preferred stock is classified as temporary equity due to redemptions provisions outside of the Company’s control.  The redeemable convertible preferred stock was converted into shares of common stock in connection with the Company’s IPO in the second quarter of 2015.  See Note 11.
Revenue recognition	Revenue recognition
	The Company recognizes revenue primarily from sales of the Argus System, sales of extended warranty service contracts for the Argus System, and from “funded software development” arrangements with collaborative parties. Revenue is recognized when the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred; the selling price is fixed or determinable; and collectability is reasonably assured. At times, the Company sells products and services, or performs software development, under multiple-element arrangements with separate units of accounting; in these situations, total consideration is allocated to the identified units of accounting based on their relative selling prices and revenue is then recognized for each unit based on its specific characteristics.
	Amounts billed to customers for shipping and handling are included in revenue when the related product or service revenue is recognized. Shipping and handling costs are included in cost of sales; the Company recognized revenue of $4,048 and $7,094 in the quarters ended March 31, 2015 and 2014, respectively, for shipping and handling.
	Revenue from sales of the Argus System
	When the Argus System is sold without the Genome Builder software, total arrangement consideration is recognized as revenue when the system is delivered to the customer. Ancillary performance obligations, including installation, limited customer training and limited consumables, are considered inconsequential and are combined with the Argus System as one unit of accounting.
	When the Argus System is sold with the Genome Builder software in a multiple-element arrangement, total arrangement consideration is allocated to the Argus System and to the Genome Builder software based on their relative selling prices. Selling prices are determined based on sales of similar systems to similar customers and, where no sales have occurred, on management’s best estimate of the expected selling price relative to similar products. Revenue related to the Argus System is recognized when it is delivered to the customer; revenue for the Genome Builder software is recognized when it is delivered to the customer.
	Revenue from sales of Genome Builder Software and consumables (on a stand-alone basis)
	Revenue is recognized for Genome Builder Software and for consumables, when sold on a standalone basis, upon delivery to the customer.
	Revenue from extended warranty service contracts
	The Company recognizes revenue associated with extended warranty service contracts over the service period in proportion to the costs expected to be incurred over that same period.
	Revenue from funded software development arrangements
	The Company’s funded software development arrangements generally consist of multiple-elements. Total arrangement consideration is allocated to the identified units of accounting based on their relative selling prices and revenue is then recognized for each unit based on its specific characteristics. When funded software development arrangements include substantive research and development milestones, revenue is recognized for each such milestone when the milestone is achieved and is due and collectible. Milestones are considered substantive if all of the following conditions are met: (1) the milestone is nonrefundable; (2) achievement of the milestone was not reasonably assured at the inception of the arrangement; (3) substantive effort is involved to achieve the milestone; and (4) the amount of the milestone appears reasonable in relation to the effort expended, the other milestones in the arrangement and the related risk associated with achievement of the milestone.
Share-based compensation	Share-based compensation
	Share-based payments are recognized at fair value. The fair value of share-based payments to employees and directors is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option.  For all time-vesting awards granted, expense is amortized using the straight-line attribution method. For awards that contain a performance condition, expense is amortized using the accelerated attribution method. Share-based compensation expense recognized is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period.
	Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.
Income taxes	Income taxes
	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to temporary differences between financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred income tax assets to the amount expected to be realized.
	Tax benefits are initially recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially, and subsequently, measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax authority, assuming full knowledge of the position and all relevant facts.
	The Company has federal net operating loss, or NOL, carryforwards of $76,267,809 at December 31, 2014. Despite the NOL carryforwards, which begin to expire in 2022, the Company may have future tax liability due to alternative minimum tax or state tax requirements. Also, use of the NOL carryforwards may be subject to an annual limitation as provided by Section 382 of the Internal Revenue Code of 1986, as amended, or the Code. There can be no assurance that the NOL carryforwards will ever be fully utilized.
Loss per share	Loss per share
	Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of shares of common stock outstanding during the period.
	For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options and stock purchase warrants using the treasury stock method, and convertible preferred stock and convertible debt using the if-converted method.
	For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive. The number of anti-dilutive shares, consisting of common stock options, restricted stock units (in 2014), stock purchase warrants, convertible preferred stock and convertible debt (in 2015) exercisable or exchangeable into common stock which have been excluded from the computation of diluted loss per share, was 8.9 million and 3.6 million for the three months ended March 31, 2015 and 2014, respectively. The Company’s convertible preferred stock contains non-forfeitable rights to dividends, and therefore are considered to be participating securities; the calculation of basic and diluted income (loss) per share excludes net income (but not net loss) attributable to the convertible preferred stock from the numerator and excludes the impact of those shares from the denominator.
Recent accounting pronouncements	Recent accounting pronouncements
	In May 2014, the Financial Accounting Standards Board, or FASB, issued guidance for revenue recognition for contracts, superseding the previous revenue recognition requirements, along with most existing industry-specific guidance. The guidance requires an entity to review contracts in five steps: 1) identify the contract, 2) identify performance obligations, 3) determine the transaction price, 4) allocate the transaction price, and 5) recognize revenue. The new standard will result in enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue arising from contracts with customers. The standard is effective for the Company’s reporting year beginning January 1, 2017 and early adoption is not permitted. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.
	In August 2014, the FASB issued guidance requiring management to evaluate on a regular basis whether any conditions or events have arisen that could raise substantial doubt about the entity’s ability to continue as a going concern. The guidance 1) provides a definition for the term ‘‘substantial doubt,’’ 2) requires an evaluation every reporting period, interim periods included, 3) provides principles for considering the mitigating effect of management’s plans to alleviate the substantial doubt, 4) requires certain disclosures if the substantial doubt is alleviated as a result of management’s plans, 5) requires an express statement, as well as other disclosures, if the substantial doubt is not alleviated, and 6) requires an assessment period of one year from the date the financial statements are issued. The standard is effective for the Company’s reporting year beginning January 1, 2017 and early adoption is permitted. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.
	In April 2015, the FASB issued accounting guidance requiring that debt issuance costs related to a recognized liability be presented on the balance sheet as a direct reduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected. The standard is effective for reporting periods beginning after December 15, 2015.  The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.
	The Company has evaluated all other issued and unadopted Accounting Standards Updates and believes the adoption of these standards will not have a material impact on its results of operations, financial position, or cash flows.

Summary_of_significant_account2

Summary of significant accounting policies (Tables)	3 Months Ended
	Mar. 31, 2015
Summary of significant accounting policies
Schedule of inventories
		March 31,			December 31,
		2015			2014
	Raw materials and supplies	$	123,569		$	40,749
	Work-in process	113,540			135,625
	Finished goods	83,698			193,368
	Total	$	320,807		$	369,742
Schedule of accrued warranty reserve, reserve expense and cost of replacement parts
		March 31,			December 31,
		2015			2014
	Balance at beginning of period and year	$	2,750		$	6,500
	Warranty expense	750			4,077
	Cost of replacement parts and related delivery	(1,500		)	(7,827		)
	Balance at end of period and year	$	2,000		$	2,750

Fair_value_measurements_Tables

Fair value measurements (Tables)	3 Months Ended
	Mar. 31, 2015
Fair value measurements
Schedule of financial assets and liabilities measured at fair value on a recurring basis
		Fair value at
		March 31,		Level 1		Level 2			Level 3
		2015
	Cash and cash equivalents	$	631,695	$	631,695	$	—		$	—
	Derivative warrant liability	$	40,502	$	—	$	—		$	40,502
		Fair value at
		December 31,		Level 1		Level 2			Level 3
		2014
	Cash and cash equivalents	$	749,517	$	748,048	$	1,469		$	—
Summary of change in fair value classified as Level 3 liabilities measured at fair value on a recurring basis
	Description	Balance at		Established		Change in			Balance at
		December		in 2015		Fair Value			March 31,
		31, 2014							2015
	Derivative warrant liability	$	—	$	72,333	$	(31,831	)	$	40,502

Stockholders_equity_deficit_Ta

Stockholders' equity (deficit) (Tables)	3 Months Ended
	Mar. 31, 2015
Stockholders' equity (deficit)
Schedule of allocation of share-based compensation expense
		Three months ended March 31,
		2015		2014
	Research and development	$	36,456	$	6,094
	General and administrative	83,299		22,060
	Sales and marketing	470,848		773
		$	590,603	$	28,927

Organization_Details

Organization (Details)	3 Months Ended
	Mar. 31, 2015
	segment
Organization
Number of business segment	1
Experience in mapping microbial and other genomes (in years)	10 years

Liquidity_and_Managements_Plan1

Liquidity and Management's Plans (Details) (USD $)	3 Months Ended		0 Months Ended	3 Months Ended	2 Months Ended	6 Months Ended	1 Months Ended	0 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	8-May-15	Sep. 30, 2014	Mar. 31, 2015	Mar. 31, 2015	Apr. 30, 2015	Dec. 31, 2014	Jan. 01, 2013	Dec. 31, 2013
								item	item
Proceeds from issuance of preferred stock		$1,420,543
Proceeds from issuance of short term notes	500,000
Subsequent Event | Initial public offering
Number of units issued under initial public offering			2,850,000
Composition of initial public offering unit, number of shares of common stock			1
Number of common shares that can be acquired upon exercise of each warrant			1
Purchase price of units issued under initial public offering (in dollars per unit)			$6
Gross proceeds from issuance of IPO			17,100,000
Demand notes converted to equity			2,100,000
Net proceeds from issuance of IPO, after considering demand notes, underwriting discounts and commissions and offering expenses			12,800,000
Subsequent Event | Initial public offering | Sales and marketing activities
Net proceeds from issuance of IPO, after considering demand notes, underwriting discounts and commissions and offering expenses			5,000,000
Subsequent Event | Initial public offering | Research and development
Net proceeds from issuance of IPO, after considering demand notes, underwriting discounts and commissions and offering expenses			4,000,000
Subsequent Event | Initial public offering | Common stock
Common stock shares issued on conversion			7,374,864
Convertible Notes Payable | 2014 Convertible Notes
Proceeds from issuance of convertible notes				1,500,000
Convertible Notes Payable | 2015 Convertible Notes
Proceeds from issuance of convertible notes					1,500,000
Short-term Demand Notes
Proceeds from issuance of short term notes						2,300,000
Repayments of notes	300,000
Short-term Demand Notes | Subsequent Event
Proceeds from issuance of short term notes							100,000
Unsecured Promissory Note | Subsequent Event
Proceeds from issuance of short term notes							200,000
Series A Preferred Stock
Number of preferred stock offerings								2	2
Proceeds from issuance of preferred stock								4,000,000	4,000,000
Demand notes converted to equity										$1,999,864
Common stock shares issued on conversion	1

Summary_of_significant_account3

Summary of significant accounting policies (Details) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Receivables
Allowance for doubtful accounts	$79,697		$79,697
Inventories
Raw materials and supplies	123,569		40,749
Work-in process	113,540		135,625
Finished goods	83,698		193,368
Total	320,807		369,742
Inventory reserve for obsolescence and expirations	871,420		867,816
Software development costs
Capitalized software cost	0		0
Product warranty
Warranty period	12 months
Balance at beginning of period and year	2,750	6,500	6,500
Warranty expense	750		4,077
Cost of replacement parts and related delivery	-1,500		-7,827
Balance at end of period and year	2,000		2,750
Impairment of long-lived assets
Impairment of long-lived assets	0	0
Deferred IPO issuance cost
Deferred legal and accounting fees	767,412		296,041
Revenue recognition
Shipping and Handling Revenue	4,048	7,094
Income taxes
NOL carryforwards			$76,267,809
Loss per share
Securities excluded from computation of diluted loss per share	8,900,000	3,600,000
Series A Convertible Redeemable Preferred Stock
Redeemable convertible preferred stock
Preferred stock, shares outstanding	3,999,864		3,999,864
Request of minimum holders' of outstanding preferred stock required for redemption (as a percent)	70
Accounts receivable | Customer Concentration Risk
Receivables
Number of customers	3
Accounts receivable | Customer Concentration Risk | Customer A
Receivables
Concentration risk (as a percent)	43.00%
Accounts receivable | Customer Concentration Risk | Customer B
Receivables
Concentration risk (as a percent)	14.00%
Accounts receivable | Customer Concentration Risk | Customer C
Receivables
Concentration risk (as a percent)	13.00%
Minimum
Receivables
Accounts receivable due (in days)	30 days
Maximum
Receivables
Accounts receivable due (in days)	45 days

Fair_value_measurements_Detail

Fair value measurements (Details) (Recurring basis, USD $)	Mar. 31, 2015	Dec. 31, 2014
Fair value measurements on recurring basis
Cash and cash equivalents	$631,695	$749,517
Derivative warrant liabilities	40,502
Level 1
Fair value measurements on recurring basis
Cash and cash equivalents	631,695	748,048
Level 2
Fair value measurements on recurring basis
Cash and cash equivalents		1,469
Level 3
Fair value measurements on recurring basis
Derivative warrant liabilities	$40,502

Fair_value_measurements_Detail1

Fair value measurements (Details 2) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Changes in the fair value of Level 3 liabilities measured at fair value on recurring basis
Fair value impairment of long-lived assets	$0	$0
Warrant
Changes in the fair value of Level 3 liabilities measured at fair value on recurring basis
Established in 2015	72,333
Change in Fair Value	-31,831
Balance at the end of the period	$40,502

Series_A_redeemable_convertibl1

Series A redeemable convertible preferred stock (Details) (Series A Preferred Stock, USD $)	1 Months Ended		3 Months Ended	12 Months Ended
	Apr. 30, 2014	Feb. 28, 2014	Mar. 31, 2015	Dec. 31, 2013	Dec. 31, 2014
			installment
			item
Series A Preferred Stock
Class of Stock
Preferred stock, shares issued	594,904	1,405,096		1,999,864
Share value (in dollars per share)				$1
Senior notes converted into shares				$1,999,864
Proceeds from issuance of convertible preferred stock	$594,904	$1,405,096
Preferred stock, shares outstanding			3,999,864		3,999,864
Number of shares of common stock into which the outstanding preferred stock can be converted			3,999,864		3,999,864
Dividend rate (as a percent)			8.00%
Liquidation and redemption preference, multiple of the purchase price			2
Number of shares issued upon conversion of stock			1
Request of minimum holders' of outstanding preferred stock required for redemption (as a percent)			70
Number of installments in redemption			3
Redemption price expressed as a multiple of the original price of preferred stock plus all accrued and unpaid dividends			2

Debt_Details

Debt (Details) (USD $)	3 Months Ended	6 Months Ended
	Mar. 31, 2015	Mar. 31, 2015
Short-term Debt
Proceeds from issuance of short term notes	$500,000
Short-term Demand Notes
Short-term Debt
Proceeds from issuance of short term notes		2,300,000
Settlement of notes	$300,000
Interest rate (as a percent)	8.00%	8.00%
Term of short-term demand notes		4 months

Debt_Details_2

Debt (Details 2) (USD $)	3 Months Ended	6 Months Ended	3 Months Ended	2 Months Ended
	Mar. 31, 2015	Mar. 31, 2015	Sep. 30, 2014	Mar. 31, 2015
Long term debt
Proceeds from issuance of short term notes	$500,000
Change in the fair value of derivative warrant liability	31,831
Short-term Demand Notes
Long term debt
Proceeds from issuance of short term notes		2,300,000
Interest rate (as a percent)	8.00%	8.00%		8.00%
2014 Convertible Notes | Convertible Notes Payable
Long term debt
Proceeds from issuance of convertible notes			1,500,000
Interest rate (as a percent)			8.00%
2015 Convertible Notes | Convertible Notes Payable
Long term debt
Proceeds from issuance of convertible notes				1,500,000
Interest rate (as a percent)	8.00%	8.00%		8.00%
Pre-payment period without penalty				3 months
Pre-payment period without penalty out of IPO				6 months
Number of shares of common stock for which detachable stock purchase warrants are exercisable	225,011	225,011		225,011
Conversion of stock exercisable price on IPO (as a percent)				110.00%
Change in the fair value of derivative warrant liability	$31,831
2015 Convertible Notes | Convertible Notes Payable | Pre IPO
Long term debt
Conversion ratio				1.25
2015 Convertible Notes | Convertible Notes Payable | Post IPO
Long term debt
Conversion ratio				1

Stockholders_equity_deficit_De

Stockholders' equity (deficit) (Details) (USD $)	3 Months Ended		0 Months Ended	1 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Oct. 24, 2014	Mar. 31, 2014	Dec. 31, 2014
Warrant
Share-based Compensation Arrangement by Share-based Payment Award
Stock purchase warrants, outstanding (in shares)	258,605				33,594
Stock options
Share-based Compensation Arrangement by Share-based Payment Award
Stock options, granted (in shares)	826,500	0
Stock options, exercise price (in dollars per share)	$0.61
Stock options, weighted average grant date fair value	$4.21
Stock options, outstanding (in shares)	1,229,494
Allocated share-based compensation expense	$590,603	$28,927
Stock options | Research and development
Share-based Compensation Arrangement by Share-based Payment Award
Allocated share-based compensation expense	36,456	6,094
Stock options | General and administrative
Share-based Compensation Arrangement by Share-based Payment Award
Allocated share-based compensation expense	83,299	22,060
Stock options | Sales and marketing activities
Share-based Compensation Arrangement by Share-based Payment Award
Allocated share-based compensation expense	470,848	773
Stock options | 2002 plan
Share-based Compensation Arrangement by Share-based Payment Award
Number of options authorized under the plan (in shares)	3,036
Maximum fair market value of incentive stock options	$100,000
Percentage of fair market value for granting stock options (as a percent)	110.00%
Minimum percentage of stockholders granted stock options at fair market value (as a percent)	10.00%
Stock options, contractual terms (in years)	10 years
Stock options, vesting percentage (as a percent)	25.00%
Stock options, exercisable period (in years)	4 years
Stock options | 2008 plan
Share-based Compensation Arrangement by Share-based Payment Award
Number of options authorized under the plan (in shares)	7,570
Number of shares available for grant under the plan (in shares)	217,992
Stock options, contractual terms (in years)	10 years
Stock options, vesting percentage (as a percent)	25.00%
Stock options, exercisable period (in years)	4 years
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award
Restricted stock units, awarded (in shares)				130,640
Restricted stock units, vested (in shares)			130,640

Commitments_and_contingencies_

Commitments and contingencies (Details) (USD $)	2 Months Ended	3 Months Ended		0 Months Ended
	Nov. 30, 2014	Mar. 31, 2015	Mar. 31, 2014	Mar. 20, 2015
				item
Operating leases
Percentage of monthly rental fee abated	50.00%
Rent expense		$183,154	$221,856
Fifth Amendment To Lease Agreement Of Corporate Facility
Operating leases
Term of lease				69 months
Number of additional five-year renewals				1
Renewal term of the lease				5 years
Fifth Amendment To Lease Agreement Of Corporate Facility | Maximum
Operating leases
Lease option term				1 year

License_agreements_research_co1

License agreements, research collaborations and development agreements (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
	agreement		item
	item
License agreements, research collaborations and development agreements
Number of license agreement in which company is a party	2
Royalty Expense	$23,028	$25,034
Future minimum royalty fees	20,000
Number of milestones achieved			16
Upfront payment received	250,000
License revenue recognized	$252,780	$627,780

Related_person_transactions_De

Related person transactions (Details) (Chief Executive Officer, USD $)	12 Months Ended
	Dec. 31, 2013
Chief Executive Officer
Related person transactions.
Related Party Transaction, Purchases from Related Party	$221,000

Subsequent_events_Details

Subsequent events (Details) (Subsequent Event, USD $)	0 Months Ended	1 Months Ended
	8-May-15	Apr. 30, 2015
Initial public offering
Subsequent events
Number of units issued under initial public offering	2,850,000
Composition of initial public offering unit, number of shares of common stock	1
Number of common shares that can be acquired upon exercise of each warrant	1
Purchase price of units issued under initial public offering (in dollars per unit)	$6
Gross proceeds from issuance of IPO	$17,100,000
Demand notes converted to equity	2,100,000
Net proceeds from issuance of IPO, after considering demand notes, underwriting discounts and commissions and offering expenses	12,800,000
Initial public offering | Sales and marketing activities
Subsequent events
Net proceeds from issuance of IPO, after considering demand notes, underwriting discounts and commissions and offering expenses	5,000,000
Initial public offering | Research and development
Subsequent events
Net proceeds from issuance of IPO, after considering demand notes, underwriting discounts and commissions and offering expenses	$4,000,000
Initial public offering | Common stock
Subsequent events
Common stock shares issued on conversion	7,374,864
Over-Allotment Option | Warrant
Subsequent events
Sale of common stock shares	422,500
2015 Plan | Common stock
Subsequent events
Number of shares authorized under the plan		1,355,000
Additional shares authorized based on outstanding shares (as a percent)		4.00%